Belfast-based data analytics firm Diaceutics has been awarded the International Star Award as part of the European Small and Mid Cap Awards 2020.
This bookends a significant period for the company, following the development and launch of its DXRX platform last month – the world’s first diagnostic network for precision medicine.
The platform is designed to improve the efficiency of cancer patient testing globally, reducing the current protracted timeline for a patient to secure optimal treatment from years to months.
The awards are a joint initiative of the European Commission, the Federation of European Securities Exchanges and European Issuers.
In June of this year, Diaceutics was recognised as ‘IPO of the Year’ at the eighth Annual Small Cap Awards, and was subsequently shortlisted for this International Star Award, alongside Proeduca Altus and Sanlorenzo, by an independent jury established by the European Commission.
RELATED: Diaceutics raises further £4m from Silicon Valley Bank to support global growth
Each year, the International Star award is bestowed upon a newly listed mid-cap company that has demonstrated strategic growth internationally, defined by critical success factors such as international sales expansion, increased profitability, and market share growth.
Small and mid-cap companies are nominated annually for four separate categories which include International Star, Rising Star, Star of Innovation and Star of 2020.
Philip White, Diaceutics CFO at Diaceutics said that the award “represents a seal of approval for the inroads we have made in recent years, particularly since our IPO. This award is really for our talented workforce, whose dedication and skill have driven this period of success for Diaceutics.”
He continued: “We will continue with our efforts to help reduce the significant lag in cancer testing and treatment. With the recent launch of DXRX, we are in a great position to make a significant impact in addressing the widespread inefficiencies in the cancer treatment landscape globally and help more patients receive the right drug at the right time.”
RELATED: Diaceutics finds sharp downturn in US cancer diagnoses due to COVID-19
For more information on DXRX – The Diagnostic Network® go to www.diaceutics.com
